Royalty Pharma plc

NasdaqGS:RPRX Stock Report

Mkt Cap: US$15.8b

Royalty Pharma Forecasted Growth

Future criteria checks 4/6

Royalty Pharma is forecasted to grow earnings and revenue by 82.7% and 7.3% per annum respectively. EPS is expected to grow by 82.6%. Return on equity is forecast to be 29.3% in 3 years.

Key information

82.7%

Earnings growth rate

82.6%

EPS growth rate

Pharmaceuticals earnings growth18.5%
Revenue growth rate7.3%
Future return on equity29.3%
Analyst coverage

Good

Last updated06 Sep 2023

Recent future growth updates

Recent updates

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Royalty Pharma: Unique Diversification, Bear Market Performer

May 26

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25
The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma Offers A Unique Long-Term Investment Opportunity

Mar 01

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Jan 25
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Jan 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Royalty Pharma: A Pharma-Like Company Without The Same Risks

Dec 27

Royalty Pharma Provides Unique Diversity To A Biopharma Portfolio

Oct 27

Royalty Pharma (RPRX) MorphoSys Transaction Call

Jun 11

Royalty Pharma: A Potentially Long-Term Dividend Investment

May 04

Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% Dividend

Mar 08
Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% Dividend

Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?

Feb 01
Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?

Royalty Pharma raises dividend by 13% to $0.17 per share

Jan 08

Earnings and Revenue Growth Forecasts

NasdaqGS:RPRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20253,0572,1802,8412,7025
12/31/20242,7566242,5102,3716
12/31/20232,9311392,6912,5706
6/30/20232,3612555222,750N/A
3/31/20232,3593323742,718N/A
12/31/20222,237434022,144N/A
9/30/20222,2475074012,064N/A
6/30/20222,2594663121,995N/A
3/31/20222,2786022631,952N/A
12/31/20212,289620-1742,018N/A
9/30/20212,286783-7322,093N/A
6/30/20212,239972-1592,132N/A
3/31/20212,195493-4962,090N/A
12/31/20202,122495-1482,035N/A
9/30/20202,0081,7451041,947N/A
6/30/20201,9341,8637931,858N/A
3/31/20201,8802,0521,0931,705N/A
12/31/20191,8142,349-541,667N/A
12/31/20181,7951,3781,3491,618N/A
12/31/20171,5981,210-8721,418N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RPRX's forecast earnings growth (82.7% per year) is above the savings rate (2.2%).

Earnings vs Market: RPRX's earnings (82.7% per year) are forecast to grow faster than the US market (15.4% per year).

High Growth Earnings: RPRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RPRX's revenue (7.3% per year) is forecast to grow slower than the US market (7.7% per year).

High Growth Revenue: RPRX's revenue (7.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RPRX's Return on Equity is forecast to be high in 3 years time (29.3%)

Discover growth companies